Close
Blog & Resources Camargo Blog January 7th, 2010

Analytical Requirements for Oral Solutions

Analytical requirements for the NDA submission of an oral solution to the FDA are very similar to those requirements for any new drug product. The analytical methods that are used for the testing of an oral solution at the NDA stage of development should be fully validated per the ICH guidelines, Q2A and Q2B, now
ICHQ2(R1) . A new drug substance specification should be set based on ICH Q6A ICHQ6A .

Very generally, the following tests are needed for release specifications;

Identification

pH

Content Uniformity

Assay

Related Substances

Residual Solvents

Microbial limits

Fill Volume

Specific gravity and viscosity may also be needed depending on the properties of the oral solution.

Certificates of analysis for three lots manufactured with the proposed commercial process should be provided.

Stability indicating methods and specifications are required, with validation. Real-time stability data to support the shelf-life on three batches that are manufactured at least one tenth of the proposed commercial batch size and with the commercial process. A minimum of 12 months of real-time data are required. Shorter time periods can be provided but the expiration date will be decided based on the length of the data submitted



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights